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Öz
(uman papillomavirus ((P6) prevelansını ve genotip dağılımının değerlendi-
rilmesi, profilaktik (P6 aşısının etkisinin iYlenmesinde ėok önemlidir. Bu ėa-
lışmanın amacı, Başkent Ďniversitesi Adana Dr. Turgut Noyan 5ygulama ve 
Araştırma MerkeYinde, bayan hastalarda (P6 prevalansı ve genotip dağılımı-
nı göstermektir. Nisan 2014 ve Kasım 2015 arasında, yaşları dağılımı 22-68 
yıl olan 268 bayan hastadan servikal örnekler toplanmıştır. (P6 DNA PC2 ile 
ėoğaltılmış ve (P6 genotiplendirmesi 2ochelinear array detection kit ile ya-
pılmıştır. (istopatolojik inceleme 146 bayan hastaya yapılmıştır. Toplamda 
268 uygun örneğin 124a ünde (46.3) (P6 iėin poYitif bulunmuştur ve bun-
ların ėoğu ;84/124 (67.7)= yüksek riskli ((2) (P6 enfeksiyonlarıdır. (P6-16 
poYitiÝiği 20.9 (n26) ve (P6-18 poYitiÝiği 4 (n5) olarak bulunmuştur. 
Grade )-))) Servikal intraepitelyal neoplasiler (C)N) de (P6 tip spesifik preve-
lansı sırasıyla 63.9, 53.8 ve 80a dir. 9üksek dereceli servikal leYyonlarda 
(P6-16 dışında diğer (2-(P6 tipleri, (P6-31, 45, 51, 53 ve 56a yı iėermekte-
dir. Sonuė olarak, hastanemiYde (P6-16 servikal leYyonlarla en sık ilişkili (P6 
genotipi olarak saptanmıştır. Bu ėalışma, ayrıca yüksek ve düşük riskli (P6 
genotiplerini aynı Yamanda birden faYla (P6 enfeksiyonların prevalansı hak-
kında da bilgi vermektedir. 
Anahtar Kelimeler
(P6 Genotiplendirme İntra Epitelya Servikal NeoplaYiler
Abstract
Assessment of (uman papillomavirus ((P6) prevalence and genotype dis-
tribution is important for monitoring the impact of prophylactic (P6 vac-
cination. This study aimed to demonstrate the (P6 prevalence and type 
distribution in women from the Baskent 5niversity Adana Dr. Turgut Noyan 
Practice and 2esearch Center. Cervical specimens from 268 women aged 
22-68 years were collected between April 2014 and November 2015.(is-
topathological examinations were performedfor 146 women. (P6 DNA was 
amplified by PC2 and (P6 and genotyping was undertaken using the 2oche 
linear array detection kit. )n total, 124 out of 268eligible samples (46.3) 
tested positive for (P6, with the majority of these ;84/124 (67.7)= having 
high-risk ((2) (P6 infection 20.9 were positive for (P616 (n26), and 4 
for (P618 (n5). (P6 type-specific prevalence was 63.9, 53.8,and 80 
among cervical intraepithelial neoplasias (C)N) Grades )-))), respectively. The 
coverage of other (2-(P6 genotypes apart from 16, included (P631, 45, 51, 
53, and 56in high-grade cervical lesions. )n conclusion, (P6-16 was identified 
as the main (P6 genotype associated with cervical disease in our hospital. 
The study reports the identification of high-and low-risk (P6 genotypes as 
well as the prevalence of multiple (P6 infections.
Keywords
(P6 Genotyping Cervical )ntraepithelial Neoplasms.
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Introduction
(uman papilloma virus ((P6) is one of the most common 
causes of sexually transmitted disease in both men and women 
worldwide. Genital (P6 infection is not a reportable disease, so 
actual incidence and prevalence figures are not known.Papil-
lomaviruses are ubiPuitous and have been detected in a wide 
variety of animals as well as in humans and are specific for 
their respective hosts. More than 200 types of (P6 have been 
recogniYed on the basis of DNA sePuence data showing genom-
ic diÛerences ;1=.
Cervical cancer (CC) represents the second-most common ma-
lignancy in women around the world and contributes to 9.8 of 
all female cancers. )ncreasing evidence suggests that multiple 
factors contribute to the development of cervical cancer, in-
cluding genetic susceptibility or host genome, co-infection of 
(P6 and other agents, and life-style factors. Based on their as-
sociation with cervical cancer and precursor lesions, (P6s can 
also be grouped into high-risk and low-risk (P6 types. ,ow-risk 
(P6 types include types 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, and 
81. (igh-risk(P6 types include types 16, 18, 31, 33, 34, 35, 39, 
45, 51, 52, 56, 58, 59, 66, 68, and 70. Although all genotypes of 
(P6 correlate with cervical cancers, (P6-16 and (P6-18 infec-
tion accounts for about 70 of all cases ;1-5=. 
Although (P6-16, 18, 31, 52, and 58 are cited among the most 
common (P6 genotypes in women with high-grade cervical le-
sions worldwide, there is significant variation in the reported 
prevalence of (2-(P6 genotypes amongcountries.Since the 
establishment of (P6 as the central cause of CC, data on (P6 
type distribution in CC have proven useful to predict the poten-
tial impact of (P616 and 18 vaccines, as well as to determine 
priorities for inclusion of carcinogenic (P6 types in future (P6 
vaccines and (P6-based screening tests ;2,3,5,6=. 
The aim of the present study was therefore to provide an esti-
mate of the background prevalence of (P6 infection and age-
specific (P6 type distrubition, and to highlight the (P6 gen-
otypes most frePuently present in cervical cancer tissue and 
precursor lesionsin Baskent 5niversity Adana Dr Turgut Noyan 
Practice and 2esearchCenter, Adana, Turkey. 
Materials and Method
Study Population
Between April 2014 and November 2015, an (P6 prevalence 
study was conducted among the female patients who attended 
the Baskent 5niversity Adana Dr. Turgut Noyan Practice and 
2esearch Center. Samples were collected from women with 
routine cervical screening. 
Cervical samples were collected with a cytobrush during gyne-
cological exaninations. This was inserted into the endocervical 
canal and then placed into the transport medium (PreservCyt 
solution (ologic, Bedford, MA, 5SA) and stored at 4C until 
DNA extraction for (P6 genotyping. 
Clinical specimens
The 268 cervical cytology specimens collected were analyYed 
for the presence of DNA of (P6. (istopathological examina-
tions were performed in 146 women by the pathologist accord-
ing to the Bethesda Diagnostic Criteria. ,esions were classified 
as normal cytology, C)N )-))), or adenocarcinoma. 
Linear Array HPV genotyping test
The ,inear Array (,A) (P6 Genotyping test is registered for 
use in Europefor detecting 37 high- and low-risk (P6 geno-
types. The test is based on four major processes: 1) DNA ex-
traction by the Ampli,ute ,iPuid Media Extraction Kit 2) PC2 
amplification of target DNA using (P6 primers 3) hybridiYation 
of the amplified products into oligonucleotide probes (,inear 
Array (P6 genotyping test) and 4) detection of probe-bound 
amplified products by colorimetric determination (,inear Array 
Detection Kit). BrieÝy, using PGM909/11 primers, a region ap-
proximately 450 base pairs in length within the ,1 gene of the 
(P6 genome was amplified by PC2. This assay simultaneously 
amplified a region within the human h globin gene as a control 
for cell adePuacy, nucleic acid extraction, and PC2 eÞciency. 
PC2 assays were performed in a reaction volume of 100 ץl, 
using 50 ץl of ,A (P6 master mix (2oche Molecular Systems) 
and 50 ץ of DNA. The amplification parameters were: 2 min at 
50C and 9 min at 95C 40 cycles of 95C for 30s, 55C for 1 
min, and 72C for 5 min or until samples were collected. Nucleic 
acid hybridiYation using a reverse line blot system was then 
performed. BrieÝy, the PC2 amplicons were denatured with the 
addition of 100 ץl of ,A denaturarion reagent (2oche Molecu-
lar Systems). Aàer 10 min at room temperature, the denatured 
amplicons (100 ץl) were hybridiYed and detected using the 
recommended ,A protocol. Thirty-seven anogenital (P6 geno-
types were detected simultaneously, including 6, 11, 16, 18, 26, 
31, 33, 35, 39, 40, 42, 45, 51-56, 58, 59, 61, 62, 64, 66-73, 
81-84, )S39, and CP6108. The ,A (P6 genotyping strips were 
visually read using the (P6 reference guide provided. 
Results
)n total, 268samples were received between April 2014 and No-
vember 2015. The 146samples were acPuired through punch 
biopsies (54.5).
Prevalence of HPV Infection
)n total 124/268 samples tested positive for (P6 (46.3), with 
the majority of those (84/124,67.7) having (2-(P6 infection, 
20.9 beingpositive for (P6-16 (n26), and 4 being positive 
for(P6-18 (n5). A total of 144/268 (53.7) of samples were 
(P6 negative.Figure outlines the overall (P6 genotype profile 
among the cohort and (P6 multiplicity. The six most common 
(P6 genotypes detected across all samples examined were 
(P6-16, (P6-CP6108 (n17), (P6-53 (n17), (P6 56 (n13), 
(P6 51 (n10), and (P6-84 (n10) (Fig.)
HPV Type-Specific Prevalence
The majority of cervical pathologies were from C)N ) cases 
(36/146, 24.7). (P6 DNA was detected in 23/36 (63.9) of 
C)N) samples, 7/13 (53.8) of C)N )) lesions, and 12/15 (80) 
of C)N ))) specimens. (P6 DNA was not detected inAC samples 
(2/146, 1.4). Table ) details the number of (P6 genotypes de-
tected by pathological subtype. /ne-third of all samples (28.8) 
had only one (P6 genotype detected (n19). (P6-16 DNA was 
present in 33.3 (5/15) of C)N ))) samples (Table ))). /ther (2-
(P6 genotypes were more prevalent in C)N )-)) pathologies. ,2-
(P6 genotypes were most common in C)N ) lesions (Table ))). 
Almost one-half (54.8) of all pathologies were (P6 negative. 
I  Journal of Clinical a d Analytical Medicine110
H V R V L   O Y  I RI U IO
The distribution of (P6 genotypes detected within each cer-
vical pathology is detailed in Table ))). (P6-16 was the most 
common (P6 detected across all cervical pathologies (Table )))). 
7e found that the prevalence of (P6 infection without cervical 
abnormalities was 39.7 (58/146).
!Ge-Specific Prevalence FOr HPV )nFecTiOn
The pathological distribution of samples by 5-year age groups 
is shown in Table )6. The mean age of women included in the 
study was 41 years (range 22-68 years, standard deviation (SD) 
9.8 years). )n total, 5 samples were from women aged 24 years 
and under,74 from thoseaged 25-34 years, and 189from those 
aged 35 years and over. C)N ) was more common in women 
aged 50-54 years and C)N ))) most common in women aged 
30-34 years (Table )6).
The number of (P6 genotypes decreased with increasing age, 
with just over half (57.2) of all (P6 infections found in tis-
sue from women aged between 40 and 44 years (Table )). Most 
tissue samples had a single (P6 genotype and this was more 
Fig. /verall (P6 genotype profile denoting the prevalence of single and multiple 
(P6 infections. (P6 genotypes omitted above (no. of single/multiple infections): 
(P6 33 (1/1), (P6 40 (2/0), (P6 64 (0/1), (P6 67 (0/1), (P6 70 (0/4), (P6 72 (0/2), 
(P6 82 (1/2), and (P6 83 (1/3).
Table ))). (P6 Genotype Distribution by Cervical Pathology
Cervical histologya n ()
(P6 genotype AC C)N ) C)N )) C)N ))) Total
(P6 16 0 2 (5.6) 1 (7.7) 5 (33.3) 8 (12.1)
(P6 31 0 1 (2.8) 2 (15.4) 1 (6.7) 4 (2.7)
(P6 18 0 2 (5.6) 1 (7.7) 0 3 (2.1)
(P6 51 0 2 (5.6) 2 (15.4) 0 4 (2.7)
(P6 45 0 2 (5.6) 1 (7.7) 1 (6.7) 4 (2.7)
(P6 39 0 1 (2.8) 0 0 1 (0.7)
(P6 58 0 1 (2.8) 0 0 1 (0.7)
(P6 66 0 1 (2.8) 0 1 (6.7) 2 (1.4)
(P6 35 0 2 (5.6) 1 (7.7) 0 3 (2.1)
(P6 6 0 2 (5.6) 0 0 2 (1.4)
(P6 73 0 1 (2.8) 0 0 1 (0.7)
(P6 53 0 3 (2.8) 0 2 (13.3) 5 (3.4)
(P6 70 0 2 (5.6) 0 1 (6.7) 3 (2.1)
(P6 42 0 2 (5.6) 0 1 (6.7) 3 (2.1)
(P6 61 0 2 (5.6) 0 2 (13.3) 4 (2.7)
(P6 11 0 2 (5.6) 0 0 2 (1.4)
(P6 CP6108 0 1 (2.8) 1 (7.7) 1 (6.7) 3 (2.1)
(P6 82 0 0 2 (15.4) 0 2 (1.4)
(P6 62 0 3 (2.8) 0 0 3 (2.1)
(P6 84 0 4 (11.1) 0 1 (6.7) 5 (3.4)
(P6 81 0 2 (5.6) 0 0 2 (1.4)
(P6 55 0 3 (2.8) 0 1 (6.7) 4 (2.7)
(P6 83 0 0 1 (7.7) 0 1 (0.7)
(P6 67 0 1 (2.8) 0 0 1 (0.7)
(P6 40 0 1 (2.8) 0 0 1 (0.7)
(P6 56 0 2 (5.6) 1 (7.7) 1 (6.7) 4 (2.7)
(P6 72 0 1 (2.8) 0 0 1 (0.7)
aSeveral patients may have had multiple (P6 genotypes on testing.
Table )). Type of (P6 Genotypes Detected by Cervical Pathology and 5-9ear 
Age Group
(P6-16 
and or 
(P6-18 
n ()
/ther high-risk 
(P6 genotypes 
n ()
,ow-risk 
(P6 
genotypes 
only n ()
(P6 
negative 
n ()
Total
Pathology
C)N ) 4 (11.1) 10 (27.7) 31 (86.1) 13 (36.1) 36
C)N )) 2 (15.4) 7 (53.8) 4 (30.8) 6 (46.2) 13
C)N ))) 5 (33.3) 3 (20) 10 (66.7) 3 (20) 15
AC 0 0 0 2 (100) 2
Age group (yrs)
5nder 25 2 (6.4) 0 2 (1.9) 3 (60) 5
25-29 3 (9.7) 17 (23.6) 11 (10.5) 14 (48.4) 31
30-34 5 (16.1) 8 (11.1) 19 (18.1) 25 (60.5) 43
35-39 5 (16.1) 16 (22.2) 19 (18.1) 35 (60.3) 58
40-44 7 (22.6) 13 (18) 26 (24.8) 21 (44.9) 49
45-49 2 (6.5) 9 (12.5) 7 (6.6) 17 (56.7) 30
50-54 2 (6.5) 4 (5.6) 14 (13.3) 18 (62.1) 29
55-59 4 (12.9) 4 (5.6) 5 (4.8) 4 (12.5) 13
60-64 0 1 (1.4) 2 (1.9) 6 (75) 8
65+ 1 (3.2) 0 0 1 (50) 2
Total n 31 72 105 144 (53.7) 268
C)N, cervical intraepithelial neoplasia (Grades )-)))) SCC, sPuamous cell carci-
noma AC, adenocarcinoma.
a)ncluding high-risk (P6 genotypes other than (P6 16/18, that is: (P6-31, 
33,35,39,45,51,52,56,58,59, and 68.
Table ). Percentage Distribution of the Number of (P6 Genotypes Detected by 
Pathological Subtype and 5-9ear Age Group
Number of (P6 genotypes detected ( of each pathology)
(P6 
negative
1 2 3 4 or 
more
Total 
n ()
Pathology
C)N ) 13 (36.1) 8 (22.2) 4 (11.1) 10 (27.8) 1 (2.8) 36 (24.7)
C)N )) 6 (46.1) 3 (23.1) 2 (15.4) 1 (7.7) 1 (7.7) 13 (8.9)
C)N ))) 3 (20) 8 (53.4) 2 (13.3) 2 (13.3) 0 15 (10.3)
AC 2 (100) 0 0 0 0 2 (1.4)
Age group (yrs)
5nder 25 3 (60) 0 2 (40) 0 0 5 (1.9)
25-29 14 (45.2) 8 (25.8) 2 (6.4) 5 (16.2) 2 (6.4) 31 (11.6)
30-34 25 (58.2) 8 (18.6) 5 (11.6) 5 (11.6) 0 43 (16)
35-39 35 (60.3) 14 (24.1) 3 (5.2) 3 (5.2) 3 (5.2) 58 (21.6)
40-44 21 (42.8) 14 (28.6) 7 (14.3) 7 (14.3) 0 49 (18.3)
45-49 17 (56.7) 9 (30) 1 (3.3) 3 (10) 0 30 (11.2)
50-54 18 (62.1) 6 (20.7) 1 (3.4) 4 (13.8) 0 29 (10.8)
55-59 4 (30.8) 7 (53.8) 0 2 (15.4) 0 13 (4.8)
60-64 6 (75) 1 (12.5) 1 (12.5) 0 0 8 (3)
65+ 1 (50) 0 0 0 1 (50) 2 (0.8)
Total 144 67 13 29 6 268
C)N, cervical intraepithelial neoplasia (Grades )-)))) AC, adenocarcinoma.
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common in those aged over 55 years. Four or more (P6 geno-
types were detected in some women and this was more com-
mon under the age of 40 years (Table )). 17 of women with 
cervical pathology had (P6-16 or (P6-18 detected, and the 
highest proportion of (P6 positive (16/18)were women aged 
40-44 years (Table ))). /ther (2-(P6 genotypes were more 
common in younger women, particularly those aged 25-29 
years. ,2-(P6 genotypes were most common in those aged 40-
44 years (Table ))).
Discussion
This was a retrospective study investigating the (P6 genotype 
distribution in women in Baskent 5niversity Adana Dr Turgut 
Noyan Practice and 2esearch Center. (2-(P6 was detected 
in 67.7 of all samples, with (P6-16 being the most common 
(20.9) (P6 genotype identified. This is consistent withpreva-
lencesdescribed elsewhere across Europe in countries such as 
Spain, Germany, Finland, North )reland, and internationally ;3, 
5, 7-9=.The prevalence of (P6 in C)N lesions in our study was 
63.9 in C)N ), 53.9  in C)N )), and 80 in C)N ))) cases. 7e 
didnat detect any (P6 DNA in AC samples across all cervical 
samples investigated. 7e found that (P6-16, CP6108, 53, 56, 
51, and 84 were the most common genotypes in all cases and 
(P6-16, 31, 45, 51, 53, 56, and 61 were the most common 
genotypes in high-grade cervical lesions. The number of (P6 
genotypes detected in the current study varied across patho-
logical grade, with the lowest percentage of single genotypes 
(22.2) in C)N ) lesions and the highest proportion (53.4) in 
C)N ))) lesions.
)n our study, the proportion of (P6 positivity (67.7) was simi-
lar to Europe (73.8), Central/South America (64.2 vs. 67.3), 
North America (76.4), Asia (66.9), Africa (70), and Turkey 
(66) ;7, 11=. (owever, our prevalence rate of (P6 16/18 (25) 
is lower than in Europe (57.6) and Africa (67.7) ;6=.
)n general, precancerous cervical lesions, i.e. C)N ))-))), have 
been accepted as a threshold of initiating definite treatment 
of precancerous lesion of sPuamous cell carcinoma (SCC). 
)dentifying (P6 genotype distribution in C)N ))-)))lesions that 
potentially progress to SCC is of utmost important in gaining 
insight into oncogenic potential of the diÛerent (P6 genotypes, 
designing protocol for screening, and estimating the eÞcacy 
of type-specific (P6 vaccines. As a substantial geographical 
variation in the (P6 genotype distribution has been observed, 
data regarding (P6 type-specific prevalence in each country 
are therefore rePuired;11,12=.
)n an examination of FFPE tissue from more than 6,000 women 
from 17 European countries using the SFF10-,iPA25 assay, 
Tjalma et al. ;13=found (P6-16 was the most frePuent (P6 type 
detected in both C)N and invasive cervical cancer. (P6-16 and/
or (P6-18 prevalence (among (P6 positive cases) was reported 
as 45.8 in C)N )) and 67.3 in C)N ))) cases, higher than in our 
study. The prevalence of (P6-16 and/or-18 in our study was 
15.4 in C)N )) cases and 33.3 in C)N ))) cases. The authors 
reported (P6-31, 33, 35, 51, 52, 58, and 68 as the most fre-
Puently detected genotypes in women with high-grade C)N le-
sions. )t has been reported that, worldwide, (P6-16 is the geno-
type with highest prevalence, followed by (P6-18 and (P6 31. 
Apart from (P6-16, we found that (P6- 31, 45, 51, 53, 56, and 
61 were the most common genotypes identified in high-grade 
lesions. A study from Turkey by Ateşer et al. found that (P6- 16, 
6, 11, 58,  and 18 were the most common genotypes identified 
in high-grade lesions ;3,10, 14, 15=.
CliÛord et al.;12=have suggested that worldwide, C)N ))-))) in-
fected with (P616, 18, or 45 are more likely to progress to SCC 
than C)N ))-))) infected with other (2 types. They performed 
a meta-analysis of published data to compare (P6 type dis-
tribution in C)N ))-))) and SCC. These data suggest that C)N 
))-))) infected with (P616, 18, and 45 more oàenprogress to 
SCC./verall, (P6 prevalence was slightly higher in SCC cases 
(87.6) than in C)N ))-))) (84.2). (P6 16 was the most common 
type in both SCC (54.3) and C)N ))-))) (45). (P618 was also 
more prevalent in SCC (12.6) than in C)N ))-))) (7). 7hen esti-
mated from studies in Asia, Europe, and South/Central America, 
respectively, there was no material diÛerence in SCC:C)N ))-))) 
ratios for (P616, (P618, (P645, (P633, (P652, or (P658. 
(owever, notably high ratios were observed for (P631 in 
South/Central America in comparison toEurope and Asia, and 
for (P658 in China (including Taiwan and (ong Kong) in com-
parison tonon-Chinese Asian countries, raising the possibility 
of localised variation in the malignant potential of particular 
(P6 types ;2,11=.
There were only two cases of AC included in the current in-
vestigation. (P6 DNA was not detected in AC samples. There-
fore our study is probably not powerful enough to investigate 
(P6 prevalence in this subgroup. A recent study in FFPE tissue 
detected using the SPF10-DE)A/,iPA25-PC2 assay reported 
thatthe prevalence of (P6-16 and/or (P6-18 was 64.3, lower 
than reported in an English multi-site investigation of (P6 DNA 
in cervical cytology and cervical cancer biopsies using the 2oche 
,inear array typing system (81.9, among (P6 positive cases) 
and among AC cases from other European studies (94.6);3=.
7e found that the prevalence of (P6 infection without cervical 
abnormalities was 39.7. Forman et al. reported that, world-
wide, the prevalence of (P6 infection without cervical abnor-
malities is 11 to 12. De Sanjosę et al. found that, overall, 
in Asia and China the prevalence of (P6 in females without cy-
tological abnormalities was 8.0 and 11.4-20.3, respectively 
(:eng2016)./gembo et al. found that (P6 infection among 
women in Africa with normal cervical cytology was 57.3 in 
Southern Africa, followed by Eastern Africa (42.2), 7estern 
Africa (7.8), and Northern Africa (12.8) ;6=.
Table )6. Age-Specific Prevalence for Cervical Pathology
Age group 
(yrs)
C)N ) 
n, ()
C)N )) 
n, ()
C)N )))
n, ()
AC 
n, ()
Total,
n ()
5nder 25 2 (1.4) 0 0 0 2 (1.4)
25-29 2 (1.4) 4 (2.7) 0 0 6 (4.1)
30-34 3 (2.1) 2 (1.4) 5 (3.4) 0 10 (6.8)
35-39 3 (2.1) 4 (2.7) 3 (2.1) 1 (0.7) 11 (7.5)
40-44 7 (4.8) 2 (1.4) 3 (2.1) 0 12 (8.2)
45-49 7 (4.8) 0 0 0 7 (4.8)
50-54 10 (6.8) 1 (0.7) 0 0 11 (7.5)
55-59 1 (0.7) 2 (1.4) 0 0 3 (2.1)
60-64 1 (0.7) 0 1 (0.7) 2 (1.4)
65+ 0 0 1 (0.7) 1 (0.7) 2 (1.4)
Total n 36 (24.7) 13 (8.9) 15 (10.3) 2 (1.4) 66 (45.2)
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A previous meta-analysis showed that, worldwide, (P6 preva-
lence was highest in the younger age categories (34 years), 
with a second peak in the older age categories (ȕ45 years). 7e 
observed a similar pattern, with peaks of prevalence in subjects 
aged 34 years and these older than 40 years. The mechanism 
of the association between (P6 infection and age is not clear. 
,ee et al. showed that changes in vaginal microbiota in post-
menopausal women made them more susceptible to (P6 infec-
tion. /ther research found that bacterial vaginosis was associ-
ated with susceptibility to (P6 infection. Moreover, the social 
activities of the younger age groups can lower immunity to (P6 
and increase chance exposure ;15, 16=.
)n this study, multiple (P6 infections were identified in 38.7 of 
the positive specimens, and the age-specific prevalence of mul-
tiple (P6 infections also showed peaks at ages 25-29 and 55-
59 years. :eng et al.;15= speculated that the decline of immuno-
surveillance in the younger and older age groups may increase 
the risk of multiple (P6 infections. Also it should be noted that 
(P6 has the ability to evadehost defenses. According to previ-
ous studies, people infected with 2 (P6 genotypes might have 
an increased risk of developing cervical cancer. (owever, the in-
teraction af various genotypes in co-infections remains unclear, 
and future studies are needed to verify whether coordinated 
mechanisms in co-infections exist.
Although we achieved a few novel findings in the present study, 
there remain other relevant factors that should be considered. 
Firstly, we collected the samples from the general female popu-
lation, and not specifically cervical cancer patients. Therefore 
the findings and conclusions drawn from this study may not be 
applicable for estimating (P6 genotype-specific prevalence in 
woman aÛected by cervical cancer. Secondly, (P6 also causes 
diseases in men, including cancer of the penis Smith et al. ;17=
reported that the prevalence of overall (P6 was 16 in men. 
(owever, the objectives of our study did not include an evalua-
tion of gender-specific prevalence of (P6 infection. )t would be 
interesting in future studies to investigate whether the preva-
lence of (P6 infection in men matches that of women, since 
vaccinating males is also considered important;15=.
)n conclusion, (P6-16 was identified as the main (P6 genotype 
associated with cervical disease in our hospital. The study re-
ports the identification of high-and low-risk (P6 genotypes as 
well as the prevalence of multiple (P6 infections. 7hen com-
paring the (P6 prevalence between countries it is important to 
consider that variations in (P6 positivity may be explained by 
diÛerences in the Puality and type of samples analyYed (biop-
sies, surgical specimens, or fresh tissue), as well as the methods 
of (P6 detection and assessment.
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